CellSource , Ltd. Receivables

CellSource , Ltd. (4880.T) currently reports a receivables of $340M as of July 2026. That compares with $340M in the prior-year period — up 0.8% year over year. Use the charts on this page to explore CellSource , Ltd.'s receivables history and peer comparisons.

CellSource , Ltd.'s receivables increased from $340M to $340M — a 0.8% year-over-year increase (period ending July 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

CellSource , Ltd. reported $340M in receivables as of July 2026. That compares with $340M in the prior-year period — up 0.8% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current receivables of $340M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for CellSource , Ltd., and consider following 4880.T for alerts when major investors trade the stock.

CellSource , Ltd. is classified in the Healthcare sector. On receivables, it currently shows $340M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing 4880.T with unrelated industries.